HopeStage
Back to all studies
CompletedNCT06423781

Long-term BHV-7000 safety study for major depression

About this titleRead the official source — NCT06423781

Researchers studied BHV-7000, tracking side effects to assess long-term safety and tolerability in people with depression.

Medication studyAges 18–75United States
The study in practice

Understand this study

What did researchers investigate?

Researchers studied BHV-7000, tracking side effects to assess long-term safety and tolerability in people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Listed locations
Chandler and 65 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 1, 2024
Recruitment status
Completed
Enrollment listed in the registry
233
Sponsor
Biohaven Therapeutics Ltd.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT06423781
Official title
Show the full official title

A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Major Depressive Disorder (MDD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Chandler · Phoenix · Little Rock

58 more locations
  • Rogers
  • Anaheim
  • Bellflower
  • Chino
  • Encino
  • Garden Grove
  • Los Angeles
  • Oceanside
  • Orange
  • Redlands
  • Riverside
  • San Jose
  • Stanford
  • Torrance
  • Upland
  • Walnut Creek
  • Colorado Springs
  • Farmington
  • Norwich
  • Jacksonville
  • Miami Lakes
  • Orlando
  • Tampa
  • West Palm Beach
  • Decatur
  • Savannah
  • Chicago
  • Elgin
  • Overland Park
  • New Orleans
  • Baltimore
  • Gaithersburg
  • Boston
  • Watertown
  • Flowood
  • St Louis
  • Las Vegas
  • Cherry Hill
  • Toms River
  • Brooklyn
  • Cedarhurst
  • Mount Kisco
  • New York
  • Staten Island
  • Dayton
  • Portland
  • Allentown
  • Media
  • Moosic
  • North Charleston
  • Austin
  • Dallas
  • DeSoto
  • Houston
  • Plano
  • Wichita Falls
  • Clinton
  • Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied BHV-7000, tracking side effects to assess long-term safety and tolerability in people with depression.

Who is behind this study?

The study sponsor is Biohaven Therapeutics Ltd.

Did this study involve medication?

Yes. The study involved medication, including BHV-7000.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies